Information  X 
Enter a valid email address

EPIC/TIDM matching '0QQ6'

Date
Time Source
Company
Announcement
07 May 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche presents data from the risdiplam pivotal FIREFISH and SUNFISH studies in spinal muscular atrophy at the 2019 AAN Annual Meeting
06 May 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche's Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
29 Apr 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio
26 Apr 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
23 Apr 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
17 Apr 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche reports a strong start in 2019 and raises the outlook for the full-year
03 Apr 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
01 Apr 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial
19 Mar 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
15 Mar 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
14 Mar 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
11 Mar 2019 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
08 Mar 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) European Commission approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
07 Mar 2019 4:35 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
  1:38 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
05 Mar 2019 1:23 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche Annual General Meeting 2019
28 Feb 2019 4:35 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
25 Feb 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche enters into definitive merger agreement to acquire Spark Therapeutics
19 Feb 2019 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants Priority Review to Roche's personalised medicine entrectinib
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma
06 Feb 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche joins the World Federation of Hemophilia Humanitarian Aid Program
05 Feb 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
01 Feb 2019 1:15 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) CHMP recommends EU approval of Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
  1:10 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
31 Jan 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche reports very strong results in 2018
30 Jan 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) - other company programmes in AD continue
17 Jan 2019 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer
17 Dec 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA)
10 Dec 2018 6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New member proposed for election to Roche Board of Directors
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Changes to the Roche Corporate Executive Committee
07 Dec 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
05 Dec 2018 1:15 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
04 Dec 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
03 Dec 2018 6:30 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
21 Nov 2018 7:15 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
13 Nov 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
01 Nov 2018 4:35 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
  6:03 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
29 Oct 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD)
24 Oct 2018 6:00 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
22 Oct 2018 3:30 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
  8:15 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone
21 Oct 2018 10:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
20 Oct 2018 3:30 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
17 Oct 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche reports very strong growth in the first nine months of 2018
15 Oct 2018 6:05 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
10 Oct 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
09 Oct 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
04 Oct 2018 5:40 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) FDA approves Roche's Hemlibra for haemophilia A without factor VIII inhibitors
  6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
03 Oct 2018 12:30 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
02 Oct 2018 6:00 am GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
25 Sep 2018 2:00 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
24 Sep 2018 2:50 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
  2:45 pm GNW Factsheet F. Hoffmann-La Roche Ltd (0QQ6) Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t